Bayer AG Stock Gains Momentum on Analyst Upgrades and US Legal Progress

Bayer AG (ISIN: DE000BAY0017) shares draw fresh investor interest amid analyst upgrades from Oddo BHF, Goldman Sachs and others, alongside a key US settlement approval in glyphosate litigation. DACH investors eye potential relief from long-standing legal burdens.

Bayer AG shares are attracting renewed attention from investors as a combination of analyst upgrades and progress in US glyphosate litigation signals a potential turning point. Major banks like Oddo BHF, Goldman Sachs, UBS and Barclays have raised price targets, citing restructuring advances, oversold technicals and legal milestones. For DACH investors, this development is particularly relevant given Bayer's status as a cornerstone of the German DAX index and its exposure to ongoing US legal risks that have weighed on the stock for years.

As of: 22.03.2026

By Dr. Elena Voss, Senior Pharma and Agri-Chemicals Analyst. Tracking Bayer's transformation amid litigation headwinds and pipeline catalysts for DACH markets.

Analyst Consensus Shifts to Bullish

Wall Street's renewed optimism is evident in recent rating changes. Oddo BHF upgraded Bayer to 'Outperform' and lifted its price target to €55 from €39.80. Goldman Sachs initiated coverage with a €54 target, while UBS moved to 'Buy' at €52 and Barclays maintained 'Overweight' at €48. These revisions reflect confidence in CEO Bill Anderson's restructuring efforts and declining short interest, which dropped nearly 50% by late February.

The Bayer AG stock closed Friday at €37.65 on the Frankfurt Stock Exchange in EUR, down 1.59% for the day but showing signs of stabilization. Its Relative Strength Index (RSI) at 20.1 indicates deeply oversold conditions, potentially setting the stage for a rebound if legal catalysts materialize.

This shift matters now because it contrasts with prior pessimism driven by litigation costs. For German-speaking investors, Bayer represents a high-conviction DAX play where resolution of US uncertainties could unlock significant upside.

Key Legal Milestone in Glyphosate Saga

A US judge granted preliminary approval to a $7.25 billion settlement for Roundup-related claims, covering a significant portion of ongoing litigation. This follows years of multibillion-dollar verdicts that have eroded shareholder value. The market now watches the US Supreme Court hearing on April 27 in Monsanto v. Durnell, with a ruling expected by late June that could preempt state failure-to-warn claims.

In Kansas, lawmakers debate a bill limiting liability for federally approved pesticides, potentially shielding Bayer from future suits. Should it pass, it could inspire similar measures elsewhere, materially reducing tail risks. Bayer still faces around 65,000 claims, but settlement progress and short interest decline suggest the worst may be priced in.

DACH investors should note Bayer's Leverkusen headquarters and DAX weighting make it a barometer for German industrials. Legal clarity would bolster balance sheet repair, directly benefiting regional portfolios heavy in blue-chip names.

Pipeline Catalysts Bolster Pharma Outlook

Bayer's pharmaceuticals division shows promise with Kerendia and Nubeqa. Phase III data expanded Kerendia's label to non-diabetic kidney disease patients, opening a market with peak sales potential over $2.6 billion annually. Nubeqa reports steady growth in oncology, diversifying revenue from crop science.

Consumer Health, featuring Aspirin and Bepanthen, generated €5.8 billion in 2025 sales. Analysts speculate a spin-off could unlock value, echoing past portfolio rationalizations post-Monsanto acquisition. These assets provide defensive qualities amid litigation noise.

For DACH markets, Bayer's pharma strength aligns with Europe's aging population and rising chronic disease prevalence. Investors in Germany, Austria and Switzerland stand to gain from reimbursed drug launches and regional dominance.

Financial Targets Amid Cash Flow Pressures

Management guides 2026 sales to €44-46 billion, EBITDA before special items to €9.1-9.6 billion, and core EPS to €4.00-4.50. Net debt targets €32-33 billion, down from €29.8 billion recently. However, negative free cash flow up to €2.5 billion looms due to €5 billion in Roundup payouts.

The 'Dynamic Shared Ownership' model aims for €2 billion in cost savings by 2026 end. 2025 adjusted EBITDA hit €9.67 billion despite a €3.62 billion net loss. Q1 results on May 12 and AGM on April 24, including a €0.11 dividend vote, loom as tests.

Bayer AG stock on Xetra traded around €38.38 in EUR as of recent sessions, reflecting resilience. DACH investors value the dividend yield and buyback potential once cash flow normalizes.

Why DACH Investors Should Watch Closely

As a DAX heavyweight, Bayer's fortunes influence German equity benchmarks tracked by funds in Germany, Austria and Switzerland. Legal resolution would reduce volatility, appealing to conservative regional portfolios. Restructuring success under Anderson could restore dividend growth, a key draw for yield-focused investors.

Europe's regulatory environment favors Bayer's crop science amid sustainability pushes. Proximity to Leverkusen HQ aids stakeholder engagement, from supplier networks to talent pools. DACH exposure to Bayer exceeds many global peers, amplifying relevance.

With shares trading at a discount to analyst targets, patient investors may find entry points. Upcoming catalysts like Supreme Court ruling and Q1 earnings heighten the case for monitoring.

Risks and Open Questions Remain

Despite positives, settlement payments strain liquidity through 2026. Failure to hit cost savings or adverse court rulings could pressure shares further. Crop science faces pricing headwinds and regulatory scrutiny on glyphosate globally.

Debt at €34.51 billion, though reduced, limits flexibility. Pipeline execution risks persist if Kerendia uptake disappoints. Macro factors like US rates and farm incomes add uncertainty.

Investors must weigh oversold technicals against fundamentals. Technical recovery hinges on breaking above the 50-day average near €42.80.

Strategic Overhaul Takes Shape

CEO Anderson's plan emphasizes operational efficiency and portfolio focus. Divesting non-core assets and streamlining divisions aim to boost margins. Consumer Health spin-off discussions resurface as value-unlocking levers.

Short interest decline signals fading bear case. With RSI extremes, tactical buyers emerge. Long-term, Bayer's diversified model across pharma, consumer and agri positions it for recovery.

For DACH investors, Bayer embodies resilient German engineering confronting global challenges. Patience amid catalysts could reward conviction holders.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.